European market authorization is not the finish line for a medical device's regulatory journey — it is the starting point for an ongoing monitoring obligation. Post-market surveillance and vigilance are the systems manufacturers use to track how devices perform once they reach real-world clinical use. This article explains the concept for procurement teams, distributors, and clinicians who want to understand what happens after a device is marketed.
What Is Post-Market Surveillance (PMS)?
Post-market surveillance refers to the proactive, systematic process manufacturers use to collect and evaluate information about a device's performance and safety throughout its time on the market. Under the applicable European medical device regulations, manufacturers are required to maintain a documented PMS plan appropriate to the device's risk class, describing how data will be gathered, analyzed, and acted upon.
Sources of PMS data can include customer feedback, complaint records, field safety reports, literature review, registry data where available, and information gathered through post-market clinical follow-up activities, depending on the device.
What Is the Difference Between PMS and Vigilance?
While closely related, PMS and vigilance serve slightly different functions:
- Post-market surveillance is the broader, ongoing monitoring activity — continuously gathering and analyzing data to confirm a device continues to perform as expected and to identify any emerging trends
- Vigilance refers more specifically to the reporting system used when a serious incident or field safety corrective action occurs — the formal process of notifying regulatory authorities about adverse events or issues that meet defined reporting thresholds
In practice, an effective vigilance system operates as a component within the manufacturer's broader PMS framework, feeding serious findings into the regulatory reporting pathway while less severe trends are tracked and analyzed through routine PMS review.
How Does Post-Market Data Feed Back Into Device Design and Quality?
Manufacturers are expected to periodically review PMS data and translate significant findings into action — whether that means updating an Instructions for Use, revising a manufacturing process, initiating a field safety corrective action, or informing future design iterations. This feedback loop is a core expectation of the internationally recognized quality management standards-aligned quality management system that underpins European market authorization, and higher-risk device classes are typically subject to more frequent and detailed periodic safety update reporting.
Notified Bodies also review a manufacturer's PMS activities as part of ongoing surveillance audits, confirming the system remains active rather than existing only on paper.
Why Does This Matter for Hospital Procurement and Distributors?
For hospital procurement and materials management teams, a manufacturer's PMS and vigilance track record is a meaningful, if sometimes overlooked, evaluation criterion. Institutions can ask prospective manufacturers about how complaints are handled, how field safety notices are communicated to customers, and how quickly issues are escalated when identified. Distributors, who often sit closest to the end customer, play an important role in this system by relaying field feedback and complaints back to the manufacturer promptly, since timely reporting supports the effectiveness of the entire vigilance chain.
Healthcare institutions and clinicians who observe unexpected device performance are generally encouraged to report such experiences to the manufacturer or relevant distributor, contributing to the broader surveillance system that benefits all users of a given device.
Frequently Asked Questions
Who is responsible for reporting a serious device-related incident?
Manufacturers hold the primary regulatory obligation for vigilance reporting, but healthcare institutions, distributors, and clinicians who become aware of an incident are generally encouraged to report it to the manufacturer promptly so the appropriate assessment and, if required, regulatory reporting can occur.
Does post-market surveillance mean a device had a known problem?
No. PMS is a standard, proactive regulatory requirement applied to all devices authorized for the European market, not an indicator that a specific problem has been identified. It functions as ongoing quality monitoring rather than a reactive measure.
How can a hospital or distributor report a device-related concern to INVAMED?
Concerns or feedback can be directed to INVAMED through the company's Contact page, which can route inquiries to the appropriate team for review.
Related INVAMED Resources
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Medical Disclaimer: This article is provided for general informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendation. It is not a substitute for consultation with a qualified healthcare professional. Product indications, availability, and regulatory status vary by country. Always refer to the official Instructions for Use (IFU) and consult a licensed physician for guidance specific to your situation. INVAMED devices are intended for use by trained healthcare professionals.